Amid a push to encourage companies and universities to register and report clinical trials in the U.K., the chair of an influential Parliamentary committee is renewing his call for violators to be sanctioned, echoing a plea made last week by a dozen patient advocacy groups.
Norman Lamb, whose Science and Technology Committee last October issued a blistering report criticizing the lack of clinical trial transparency, again urged the U.K.’s Health Research Authority to enforce rules and impose penalties on companies on wayward trial sponsors and investigators.
The agency “must follow my committee’s recommendation last autumn to introduce a system of sanctions for those who do not comply with reporting results requirements for clinical trials. For too long there has been little consequence to non-compliance with current requirements and it’s time action was taken,” he said in his statement, which was issued late last week.
About the Author Reprints
